CD13 Antibodies

Santa Cruz Biotechnology features a diverse variety of CD13 Antibodies for investigating CD13's role in various biological processes. CD13 Antibodies are validated for western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), flow cytometry (FCM), and enzyme-linked immunosorbent assay (ELISA). CD13, also known as aminopeptidase N, is a type II transmembrane protein that plays a crucial role in regulating immune responses and metabolizing bioactive peptides. CD13 actively participates in cell adhesion, migration, and differentiation processes, making it a significant focus in cancer research and therapeutic development. The expression of CD13 is frequently detected in specific tumor types, emphasizing its importance in oncology studies. Researchers worldwide rely on CD13 monoclonal antibodies to advance their understanding of cellular mechanisms and pathways. CD13 monoclonal antibodies enable detailed examination of protein expression patterns and interactions in normal and disease states. Santa Cruz Biotechnology monoclonal antibodies for CD13 continue to support breakthrough discoveries in biomedical research and therapeutic development.